Zibing Wang

1.1k total citations
42 papers, 765 citations indexed

About

Zibing Wang is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Zibing Wang has authored 42 papers receiving a total of 765 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 19 papers in Immunology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Zibing Wang's work include Cancer Immunotherapy and Biomarkers (23 papers), Immune Cell Function and Interaction (15 papers) and Immunotherapy and Immune Responses (11 papers). Zibing Wang is often cited by papers focused on Cancer Immunotherapy and Biomarkers (23 papers), Immune Cell Function and Interaction (15 papers) and Immunotherapy and Immune Responses (11 papers). Zibing Wang collaborates with scholars based in China, United States and United Kingdom. Zibing Wang's co-authors include Quanli Gao, Brian G. Till, Zhihai Qin, Yuqing Liu, Jing Jiang, Jinhua Zhang, Zhiguang Li, Yiman Shang, Xiaolin Wei and Feng Bin and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Zibing Wang

42 papers receiving 760 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zibing Wang China 14 400 321 141 122 91 42 765
Zengfu Zhang China 10 251 0.6× 129 0.4× 157 1.1× 159 1.3× 64 0.7× 22 675
Qianxia Zhang China 14 574 1.4× 866 2.7× 240 1.7× 82 0.7× 55 0.6× 26 1.4k
Changli Peng China 6 107 0.3× 104 0.3× 66 0.5× 42 0.3× 69 0.8× 8 324
Xueke Shi China 14 168 0.4× 83 0.3× 224 1.6× 64 0.5× 363 4.0× 22 907
Clément Anfray Italy 15 194 0.5× 430 1.3× 190 1.3× 61 0.5× 68 0.7× 25 740
Wen‐Pin Su Taiwan 16 362 0.9× 84 0.3× 411 2.9× 311 2.5× 115 1.3× 39 986
Fuqiang Shao China 16 249 0.6× 42 0.1× 142 1.0× 118 1.0× 66 0.7× 76 806
Zhaoyong Liu China 13 117 0.3× 72 0.2× 267 1.9× 76 0.6× 45 0.5× 29 535
Mingen Liu United States 8 271 0.7× 380 1.2× 189 1.3× 59 0.5× 37 0.4× 14 678
Hye Seon Park South Korea 15 330 0.8× 275 0.9× 149 1.1× 63 0.5× 150 1.6× 24 714

Countries citing papers authored by Zibing Wang

Since Specialization
Citations

This map shows the geographic impact of Zibing Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zibing Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zibing Wang more than expected).

Fields of papers citing papers by Zibing Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zibing Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zibing Wang. The network helps show where Zibing Wang may publish in the future.

Co-authorship network of co-authors of Zibing Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Zibing Wang. A scholar is included among the top collaborators of Zibing Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zibing Wang. Zibing Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wang, Chenwei, Jiewen Chen, Jingyao Li, et al.. (2024). An EBV-related CD4 TCR immunotherapy inhibits tumor growth in an HLA-DP5+ nasopharyngeal cancer mouse model. Journal of Clinical Investigation. 134(8). 3 indexed citations
3.
Sharma, Amit, Xiubao Ren, Antonio Rosato, et al.. (2024). Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy. Cancer Immunology Immunotherapy. 73(2). 21–21. 7 indexed citations
4.
Fu, Xiaomin, Peng Qin, Yong Zhang, et al.. (2023). The inter-link of ageing, cancer and immunity: findings from real-world retrospective study. Immunity & Ageing. 20(1). 75–75. 9 indexed citations
5.
Bin, Liang, Zibing Wang, Xiaoyu Fan, et al.. (2023). Thermodynamic Insights into Sustainable Aviation Fuel Synthesis via CO/CO2 Hydrogenation. Catalysts. 13(11). 1396–1396. 4 indexed citations
6.
Liu, Huan, Yang Zhao, Zibing Wang, et al.. (2023). Evolution of reaction mechanism in the catalytic combustion of ammonia on copper-cerium mixed oxide. Journal of Catalysis. 425. 20–31. 9 indexed citations
7.
Wang, Linlin, et al.. (2023). Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer. Frontiers in Immunology. 14. 1256740–1256740. 4 indexed citations
8.
Fu, Qiang, Lingdi Zhao, Xiaomin Fu, et al.. (2022). Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma. The Oncologist. 27(6). e463–e470. 9 indexed citations
9.
Zhu, Li, et al.. (2022). Identification of an immune gene-associated prognostic signature in patients with bladder cancer. Cancer Gene Therapy. 29(5). 494–504. 7 indexed citations
10.
Peng, Ling, Yuqing Liu, Brian G. Till, et al.. (2022). Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients. Cancer Immunology Immunotherapy. 72(2). 437–448. 15 indexed citations
11.
Wang, Zibing, Yuqing Liu, Ling Peng, et al.. (2022). Role of fibrosarcoma-induced CD11b+ myeloid cells and tumor necrosis factor-α in B cell responses. Oncogene. 41(10). 1434–1444. 5 indexed citations
12.
13.
Peng, Ling, Bicheng Zhang, Brian G. Till, et al.. (2022). Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies. Frontiers in Immunology. 13. 882172–882172. 4 indexed citations
14.
Wang, Weiwei, Zibing Wang, Jinchuan Yang, et al.. (2021). Exploration of the potential mechanism of Banxia Xiexin Decoction for the effects on TNBS-induced ulcerative colitis rats with the assistance of network pharmacology analysis. Journal of Ethnopharmacology. 277. 114197–114197. 32 indexed citations
15.
Yang, Yonghao, et al.. (2021). Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma. Frontiers in Immunology. 12. 728750–728750. 4 indexed citations
16.
Liu, Yuqing, et al.. (2020). Pretreatment Peripheral B Cells Are Associated With Tumor Response to Anti-PD-1-Based Immunotherapy. Frontiers in Immunology. 11. 563653–563653. 22 indexed citations
17.
18.
Wang, Zibing, Yong Zhang, Yuqing Liu, et al.. (2013). Association of Myeloid-derived Suppressor Cells and Efficacy of Cytokine-induced Killer Cell Immunotherapy in Metastatic Renal Cell Carcinoma Patients. Journal of Immunotherapy. 37(1). 43–50. 40 indexed citations
19.
Wang, Zibing, Jing Jiang, Zhiguang Li, et al.. (2010). A Myeloid Cell Population Induced by Freund Adjuvant Suppresses T-cell−mediated Antitumor Immunity. Journal of Immunotherapy. 33(2). 167–177. 29 indexed citations
20.
Li, Zhiguang, Jing Jiang, Zibing Wang, et al.. (2008). Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis. Cancer Research. 68(21). 8687–8694. 91 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zengfu Zhang Breakdown of academic impact, for papers by Qianxia Zhang Breakdown of academic impact, for papers by Changli Peng Breakdown of academic impact, for papers by Xueke Shi Breakdown of academic impact, for papers by Clément Anfray Breakdown of academic impact, for papers by Wen‐Pin Su Breakdown of academic impact, for papers by Fuqiang Shao Breakdown of academic impact, for papers by Zhaoyong Liu Breakdown of academic impact, for papers by Mingen Liu Breakdown of academic impact, for papers by Hye Seon Park
Rankless by CCL
2026